Parathyroid Carcinoma

Chapter

Abstract

Parathyroid carcinoma is a rare malignant neoplasm derived from the parenchymal cells of the parathyroid gland. The first description of this malignant tumor was by de Quevain in 1904. Making up only a small percentage of parathyroid carcinomas seen today, the first tumor described was actually a nonfunctioning tumor. It was not until 1933 when Sainton and Millot first described a case of metastatic parathyroid carcinoma causing manifestations of Recklinghausen disease, commonly known today as hyperparathyroidism (HPTH). Parathyroid carcinoma is an uncommon cause of PTH-dependant hypercalcemia accounting for only 1–3% of cases of primary HPTH. Since de Quevain’s initial article, there have been over 800 cases reported in the literature. From these reports, it is apparent that parathyroid cancer characteristically presents with more profound manifestations of HPTH than parathyroid adenomas and benign hyperplasia.

Keywords

Parathyroid Gland Recurrent Laryngeal Nerve Multiple Endocrine Neoplasia Type Parathyroid Adenoma Bloc Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    de Quevain F (1904) Parastruma maligigna aberrata. Deutsche Zeitschr Chir 100:334–352CrossRefGoogle Scholar
  2. 2.
    Sainton P, Millot J (1933) Malegne d’un adenome parathyroidiene eosinophile. Au cours d’une de Reckinghausen. Ann Anat Pathol 10:813–814Google Scholar
  3. 3.
    Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86(2):485–493PubMedCrossRefGoogle Scholar
  4. 4.
    Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 71(4):197–205PubMedCrossRefGoogle Scholar
  5. 5.
    Obara T, Fujimoto Y (1991) Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 15(6):738–744PubMedCrossRefGoogle Scholar
  6. 6.
    Wang CA, Gaz RD (1985) Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149(4):522–527PubMedCrossRefGoogle Scholar
  7. 7.
    Cohn K, Silverman M, Corrado J, Sedgewick C (1985) Parathyroid carcinoma: the Lahey Clinic experience. Surgery 98(6):1095–1100PubMedGoogle Scholar
  8. 8.
    Hakaim AG, Esselstyn CB (1993) Parathyroid carcinoma: 50-year experience at the Cleveland Clinic Foundation. Cleve Clin J Med 60:331–335PubMedGoogle Scholar
  9. 9.
    Fujimota Y, Obara T (1987) How to recognize and treat parathyroid carcinoma. Surg Clin North Am 67:343–357Google Scholar
  10. 10.
    DeLellis RA, Mazzaglia P, Mangray S (2008) Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132:1251–1262PubMedGoogle Scholar
  11. 11.
    Rodgers SE, Perrier ND (2006) Parathyroid carcinoma. Curr Opin Oncol 18:16–22PubMedCrossRefGoogle Scholar
  12. 12.
    Beus KS, Stack BC Jr (2004) Parathyroid carcinoma. Otolaryngol Clin North Am 37:845–854PubMedCrossRefGoogle Scholar
  13. 13.
    Shane E (1994) Parathyroid carcinoma. Curr Ther Endocrinol Metab 5:565–568Google Scholar
  14. 14.
    Salusky IB, Goodman WG, Kuizon BD (2000) Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism. Pediatr Nephrol 14:641–645PubMedCrossRefGoogle Scholar
  15. 15.
    Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo L-O (1992) Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16:724–731PubMedCrossRefGoogle Scholar
  16. 16.
    Miki H, Sumitomo M, Inoue H, Kita S, Monden Y (1996) Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 120(5):897–901PubMedCrossRefGoogle Scholar
  17. 17.
    Streeten EA, Weinstein LS, Norton JA, Mulvihill JJ, White BJ, Friedman E, Jaffe G, Brandi ML, Stewart K, Zimering MB (1992) Studies in a kindred with parathyroid carcinoma. J Clin Endocrinol Metab 75(2):362–366PubMedCrossRefGoogle Scholar
  18. 18.
    Cordeiro AC, Montenegro FL, Kulcsar MA, Dellanegra LA, Tavares MR, Michaluart P Jr, Ferraz AR (1998) Parathyroid carcinoma. Am J Surg 175(1):52–55PubMedCrossRefGoogle Scholar
  19. 19.
    Chow E, Tsang RW, Brierley JD, Filice S (1998) Parathyroid carcinoma – the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 41(3):569–572PubMedCrossRefGoogle Scholar
  20. 20.
    Mashburn MA, Chonkich GD, Chase DR, Petti GH Jr (1987) Parathyroid carcinoma: two new cases – diagnosis, therapy, and treatment. Laryngoscope 97(2):215–218PubMedCrossRefGoogle Scholar
  21. 21.
    de Papp AE, Kinder B, LiVolsi V, Gupta SM, Stewart AF (1994) Parathyroid carcinoma arising from parathyroid hyperplasia: autoinfarction following intravenous treatment with pamidronate. Am J Med 97(4):399–400PubMedCrossRefGoogle Scholar
  22. 22.
    Favia G, Lumachi F, Polistina F, D’Amico DF (1998) Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22(12):1225–1230PubMedCrossRefGoogle Scholar
  23. 23.
    Hauptman JB, Modlinger RS, Ertel NH (1983) Pheochromocytoma resistant to alpha adrenergic blockade. Arch Intern Med 143:2321–2323PubMedCrossRefGoogle Scholar
  24. 24.
    Kebebew E, Arici C, Duh QY, Clark OH (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878–885PubMedCrossRefGoogle Scholar
  25. 25.
    Dionisi S, Minisola S, Pepe J, De Geronimo S, Paglia F, Memeo L, Fitzpatrick LA (2002) Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 77:866–869PubMedCrossRefGoogle Scholar
  26. 26.
    Schmidt JL, Perry RC, Philippsen LP, Wu HH (2002) Intrathyroidal parathyroid carcinoma presenting with only hypercalcemia. Otolaryngol Head Neck Surg 127:352–353PubMedCrossRefGoogle Scholar
  27. 27.
    Chandran M, Deftos L, Stuenkel C, Haghihi P, Orloff L (2003) Thymic parathyroid carcinoma and postoperative hungry bone syndrome. Am Surg 9:152–156Google Scholar
  28. 28.
    Aldinger KA, Hickey RC, Ibanez ML, Samaan NA (1982) Parathyroid carcinoma: a clinical study of seven cases of functioning and two cases of nonfunctioning parathyroid cancer. Cancer 49:388–397PubMedCrossRefGoogle Scholar
  29. 29.
    Snell SB, Gaar EE, Stevens SP, Flynn MB (2003) Parathyroid cancer, a continued diagnostic and therapeutic dilemma: report of four cases and review of the literature. Am Surg 69:711–716PubMedGoogle Scholar
  30. 30.
    Iacobone M, Lumachi F, Favia G (2004) Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 88:223–228PubMedCrossRefGoogle Scholar
  31. 31.
    Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736–1741PubMedCrossRefGoogle Scholar
  32. 32.
    Okamoto T, Iihara M, Obara T, Tsukada T (2009) Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg 33:2343–2354PubMedCrossRefGoogle Scholar
  33. 33.
    Talat N, Schulte KM (2010) Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol 17:2156–2174PubMedCrossRefGoogle Scholar
  34. 34.
    Morrison C, Farrar W, Kneile J, Williams N, Liu-Stratton Y, Bakaletz A, Aldred MA, Eng C (2004) Molecular classification of parathyroid neoplasia by gene expression profiling. Am J Pathol 165(2):565–576PubMedCrossRefGoogle Scholar
  35. 35.
    Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V (1995) Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56:944–950PubMedGoogle Scholar
  36. 36.
    Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40(9):657–663PubMedCrossRefGoogle Scholar
  37. 37.
    Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729PubMedCrossRefGoogle Scholar
  38. 38.
    Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94:434–441PubMedCrossRefGoogle Scholar
  39. 39.
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86(3):538–544PubMedCrossRefGoogle Scholar
  40. 40.
    Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32(4):676–680PubMedCrossRefGoogle Scholar
  41. 41.
    Ishida T, Yokoe T, Izuo M (1991) Nationwide survey of parathyroid operations in Japan 1980–1989. Endocr Surg 8:37–45Google Scholar
  42. 42.
    Ireland JP, Fleming SJ, Levison DA, Cattell WR, Baker LR (1985) Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 38:1114–1118PubMedCrossRefGoogle Scholar
  43. 43.
    Smith JF (1993) The pathological diagnosis of carcinoma of the parathyroid. Clin Endocrinol (Oxf) 38:662CrossRefGoogle Scholar
  44. 44.
    Christmas TJ, Chapple CR, Noble JG, Milroy EJ, Cowie AG (1988) Hyperparathyroidism after neck irradiation. Br J Surg 75(9):873–874PubMedCrossRefGoogle Scholar
  45. 45.
    Tisell LE, Hansson G, Lindberg S, Ragnhult I (1977) Hyperparathyroidism in persons treated with X-rays for tuberculous cervical adenitis. Cancer 40:846–854PubMedCrossRefGoogle Scholar
  46. 46.
    Goldman L, Smyth FS (1936) Hyperparathyroidism in siblings. Ann Surg 104:971–981PubMedCrossRefGoogle Scholar
  47. 47.
    Huang S-M, Duh Q-Y, Shaver J, Siperstein AE, Kraimps J-L, Clark OH (1997) Familial hyperparathyroidism without multiple endocrine neoplasia. World J Surg 21:22–29PubMedCrossRefGoogle Scholar
  48. 48.
    Barry MK, van Heerden JA, Grant CS, Thompson GB, Khosla S (1997) Is familial hyperparathyroidim a unique disease. Surgery 122:1028–1033PubMedCrossRefGoogle Scholar
  49. 49.
    Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ, Larsson C (1993) Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77(6):1485–1489PubMedCrossRefGoogle Scholar
  50. 50.
    Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart T, Mallette LE (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108:1006–1013PubMedGoogle Scholar
  51. 51.
    Haven CJ, Wong FK, van Dam EW, van der Juijt R, van Asperen C, Jansen J, Rosenberg C, de Wit M, Roijers J, Hoppener J, Lips CJ, Larsson C, Teh BT, Morreau H (2000) A genotypic and histopathological study of a large Dutch ­kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 85(4):1449–1454PubMedCrossRefGoogle Scholar
  52. 52.
    Cavaco BM, Guerra L, Bradley KJ, Carvalho D, Harding B, Oliveira A, Santos MA, Sobrinho LG, Thakker RV, Leite V (2004) Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 89(4):1747–1752PubMedCrossRefGoogle Scholar
  53. 53.
    Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, Yap A, Epstein M, Heath H III, Cameron D, Larsson C (1996) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 81(12):4204–4211PubMedCrossRefGoogle Scholar
  54. 54.
    Cavaco BM, Barros L, Pannett AA, Ruas L, Carvalheiro M, Ruas MM, Krausz T, Santos MA, Sobrinho LG, Leite V, Thakker RV (2001) The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. QJM 94(4):213–222PubMedCrossRefGoogle Scholar
  55. 55.
    Wassif WS, Farnebo F, Teh BT, Moniz CF, Li FY, Harrison JD, Peters TJ, Larsson C, Harris P (1999) Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 50(2):191–196CrossRefGoogle Scholar
  56. 56.
    Haven CJ, Howell VM, Eilers PH, Dunne R, Takahashi M, van Puijenbroek M, Furge K, Kievit J, Tan MH, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Dralle H, Hoang-Vu C, Gimm O, Morreau H, Marsh DJ, Teh BT (2004) Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64:7405–7411PubMedCrossRefGoogle Scholar
  57. 57.
    Weinstein LS, Simonds WF (2003) HRPT2, a marker of parathyroid cancer. N Engl J Med 349(18):1691–1692PubMedCrossRefGoogle Scholar
  58. 58.
    Farnebo F, Teh BT, Dotzenrath C, Wassif WS, Svensson A, White I, Betz R, Goretzki P, Sandelin K, Farnebo LO, Larsson C (1997) Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Hum Genet 99:342–349PubMedCrossRefGoogle Scholar
  59. 59.
    Farnebo F, Teh BT, Kytola S, Svensson A, Phelan C, Sandelin K, Thompson NW, Hoog A, Weber G, Farnebo LO, Larsson C (1998) Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 83(8):2627–2630PubMedCrossRefGoogle Scholar
  60. 60.
    Dwight T, Twigg S, Delbridge L, Wong FK, Farnebo F, Richardson AL, Nelson A, Zedenius J, Philips J, Larsson C, Teh BT, Robinson B (2000) Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clin Endocrinol (Oxf) 53:85–92CrossRefGoogle Scholar
  61. 61.
    Mallya SM, Arnold A (2000) Cyclin D1 in parathyroid disease. Front Biosci 5:D367–D371PubMedCrossRefGoogle Scholar
  62. 62.
    Hemmer S, Wasenius VM, Haglund C, Zhu Y, Knuutila S, Franssila K, Joensuu H (2001) Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 158(4):1355–1362PubMedCrossRefGoogle Scholar
  63. 63.
    Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA (1999) Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12(4):412–416PubMedGoogle Scholar
  64. 64.
    Hsi ED, Zukerberg LR, Yang WI, Arnold A (1996) Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81(5):1736–1739PubMedCrossRefGoogle Scholar
  65. 65.
    Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RS, Arnold A (2003) Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 59(2):180–189CrossRefGoogle Scholar
  66. 66.
    Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV (1996) Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 45(2):195–200CrossRefGoogle Scholar
  67. 67.
    Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A (1994) Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330(11):757–761PubMedCrossRefGoogle Scholar
  68. 68.
    Venkitaraman AR (2001) Chromosome stability, DNA recombination and the BRCA2 tumour suppressor. Curr Opin Cell Biol 13(3):338–343PubMedCrossRefGoogle Scholar
  69. 69.
    Mittendorf E, McHenry CR (2005) Parathyroid carcinoma. J Surg Oncol 89:137–142CrossRefGoogle Scholar
  70. 70.
    Pasieka JL (1999) Parathyroid carcinoma. Oper Tech Gen Surg 1:71–84CrossRefGoogle Scholar
  71. 71.
    Koea JB, Shaw JH (1999) Parathyroid cancer: biology and management. Surg Oncol 8(3):155–165PubMedCrossRefGoogle Scholar
  72. 72.
    Silverberg SJ, Bilezikian JP (1997) Primary hyperparathyroidism: still evolving? J Bone Miner Res 12:856–862PubMedCrossRefGoogle Scholar
  73. 73.
    Silverberg SJ, Bilezikian JP (1996) Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 81:2036–2040PubMedCrossRefGoogle Scholar
  74. 74.
    Heath H III, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism. Incidence, morbidity, and potential ­economic impact in a community. N Engl J Med 302(4):189–193PubMedCrossRefGoogle Scholar
  75. 75.
    Klink BK, Karulf RE, Maimon WN, Peoples JB (1991) Nonfunctioning parathyroid carcinoma. Am Surg 57:463–467PubMedGoogle Scholar
  76. 76.
    Murphy MN, Glennon PG, Diocee MS, Wick MR, Cavers DJ (1986) Nonsecretory parathyroid carcinoma of the mediastinum. Light microscopic, immunocytochemical, and ultrastructural features of a case, and review of the literature. Cancer 58:2468–2476PubMedCrossRefGoogle Scholar
  77. 77.
    Palazzo F, Delbridge LW (2004) Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism. Surg Clin North Am 84:717–734PubMedCrossRefGoogle Scholar
  78. 78.
    Edmonson GR, Charboneau JW, James EM, Reading CC, Grant CS (1986) Parathyroid carcinoma: high-frequency sonographic features. Radiology 161:65–67PubMedGoogle Scholar
  79. 79.
    Kinoshita Y, Fukase M, Uchihashi M, Takenaka M, Hishikawa R, Nakada M, Nonaka H, Kondo T, Fujita T (1985) Significance of preoperative use of ultrasonography in parathyroid neoplasms: comparison of sonographic textures with histologic findings. J Clin Ultrasound 13:457–460PubMedCrossRefGoogle Scholar
  80. 80.
    Johnston LB, Carroll MJ, Britton KE, Lowe DG, Shand W, Besser GM, Grossman AB (1996) The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. J Clin Endocrinol Metab 81(1):346–352PubMedCrossRefGoogle Scholar
  81. 81.
    Thompson SD, Prichard AJ (2004) The management of parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg 12:93–97PubMedCrossRefGoogle Scholar
  82. 82.
    Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P (2000) Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 23:255–257PubMedGoogle Scholar
  83. 83.
    Clayman GL, Gonzalez HE, El Naggar A, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100(5):900–905PubMedCrossRefGoogle Scholar
  84. 84.
    Ippolito G, Palazzo FF, Sebag F, De MC, Henry JF (2007) Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94:566–570PubMedCrossRefGoogle Scholar
  85. 85.
    Vetto JT, Brennan MF, Woodruf J, Burt M (1993) Parathyroid carcinoma: diagnosis and clinical history. Surgery 114:882–892PubMedGoogle Scholar
  86. 86.
    Munson ND, Foote RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, van Heerden JA, Thompson GB, Lloyd RV (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378–2384PubMedCrossRefGoogle Scholar
  87. 87.
    Anderson BJ, Samaan NA, Vassilopoulou-Sellin R, Ordonez NG, Hickey RC (1983) Parathyroid carcinoma: features and difficulties in diagnosis and management. Surgery 94(6):906–915PubMedGoogle Scholar
  88. 88.
    Grammes CF, Eyerly RC (1980) Hyperparathyroidism and parathyroid carcinoma. South Med J 73:814–816PubMedCrossRefGoogle Scholar
  89. 89.
    Boneson L, Grimulius L, Delellis RA (2004) World Health Organization classification of tumors, pathology and ­genetics: tumors of endocrine organs. IARC Press, Lyon, pp 124–127Google Scholar
  90. 90.
    Kleinpeter KP, Lovato JF, Clark PB, Wooldridge T, Norman ES, Bergman S, Perrier ND (2005) Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol 12:260–266PubMedCrossRefGoogle Scholar
  91. 91.
    Schantz A, Castleman B (1973) Parathyroid carcinoma. A study of 70 cases. Cancer 31:600–605PubMedCrossRefGoogle Scholar
  92. 92.
    Sandelin K, Tullgren O, Farnebo LO (1994) Clinical course of metastatic parathyroid cancer. World J Surg 18:594–598PubMedCrossRefGoogle Scholar
  93. 93.
    Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, Brennan MF, Singh B, Ghossein RA (2003) Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 34:54–64PubMedCrossRefGoogle Scholar
  94. 94.
    DeLellis RA (1995) Does the evaluation of proliferative activity predict malignancy of prognosis in endocrine tumors? Hum Pathol 26:131–134PubMedCrossRefGoogle Scholar
  95. 95.
    Bondeson L, Sandelin K, Grimelius L (1993) Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17:820–829PubMedCrossRefGoogle Scholar
  96. 96.
    Busaidy NL, Jimenez C, Habra MA, Schultz PN, El Naggar AK, Clayman GL, Asper JA, Diaz EM Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26:716–726PubMedCrossRefGoogle Scholar
  97. 97.
    Faccini JM (1970) The ultrastructure of parathyroid glands removed from patients with primary hyperparathyroidism: a report of 40 cases, including four carcinomata. J Pathol 102:189–199PubMedCrossRefGoogle Scholar
  98. 98.
    Levin KE, Chew KL, Ljung B, Mayall BH, Siperstein AE, Clark OH (1988) Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab 67(4):779–784PubMedCrossRefGoogle Scholar
  99. 99.
    Mallette LE (1992) DNA quantitation in the study of parathyroid lesions. Am J Clin Pathol 98:305–311PubMedGoogle Scholar
  100. 100.
    Harlow S, Roth SI, Bauer K, Marshall RB (1991) Flow cytometric DNA analysis of normal and pathologic parathyroid glands. Mod Pathol 4:310–315PubMedGoogle Scholar
  101. 101.
    Abbona GC, Papotti M, Gasparri G, Bussolati G (1995) Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 26:135–138PubMedCrossRefGoogle Scholar
  102. 102.
    Farnebo F, Auer G, Farnebo LO, Teh BT, Twigg S, Aspenblad U, Thompson NW, Grimelius L, Larsson C, Sandelin K (1999) Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23:68–74PubMedCrossRefGoogle Scholar
  103. 103.
    Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPTH-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–1149PubMedGoogle Scholar
  104. 104.
    Bilezikian JP (1992) Management of acute hypercalcemia. N Engl J Med 326(18):1196–1203PubMedCrossRefGoogle Scholar
  105. 105.
    Sandelin K, Thompson NW, Bondeson L (1991) Metastatic parathyroid carcinoma: dilemmas in management. Surgery 110:978–988PubMedGoogle Scholar
  106. 106.
    Hurtado J, Esbrit P (2002) Treatment of malignant hypercalcaemia. Expert Opin Pharmacother 3:521–527PubMedCrossRefGoogle Scholar
  107. 107.
    Major PP, Coleman RE (2001) Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol 28:17–24PubMedCrossRefGoogle Scholar
  108. 108.
    Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83(4):1083–1088PubMedCrossRefGoogle Scholar
  109. 109.
    Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95(7):4040–4045PubMedCrossRefGoogle Scholar
  110. 110.
    Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet ­normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88(12):5644–5649PubMedCrossRefGoogle Scholar
  111. 111.
    Peacock M (2004) Clinical effects of calcimimetics in hyperparathyroidism. J Musculoskelet Neuronal Interact 4:414–415PubMedGoogle Scholar
  112. 112.
    Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A (2004) Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413–3420PubMedCrossRefGoogle Scholar
  113. 113.
    Koyano H, Shishiba Y, Shimizu T, Suzuki N, Nakazawa H, Tachibana S, Murata H, Furui S (1994) Successful treatment by surgical removal of bone metastasis producing PTH: new approach to the management of metastatic parathyroid carcinoma. Intern Med 33:697–702PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Surgery, Faculty of MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Department of PathologyUniversity of CalgaryCalgaryCanada
  3. 3.Calgary Laboratory ServicesCalgaryCanada

Personalised recommendations